Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy.
about
The detection of significant prostate cancer is correlated with the Prostate Imaging Reporting and Data System (PI-RADS) in MRI/transrectal ultrasound fusion biopsy.Identification of FISH biomarkers to detect chromosome abnormalities associated with prostate adenocarcinoma in tumour and field effect environment.Real-time Virtual Sonography for navigation during targeted prostate biopsy using magnetic resonance imaging data.Nanocytological field carcinogenesis detection to mitigate overdiagnosis of prostate cancer: a proof of concept studyProstate cancer detection rates of magnetic resonance imaging-guided prostate biopsy related to Prostate Imaging Reporting and Data System score.High-Resolution Rapid Diagnostic Imaging of Whole Prostate Biopsies Using Video-Rate Fluorescence Structured Illumination MicroscopyThe addition of a sagittal image fusion improves the prostate cancer detection in a sensor-based MRI /ultrasound fusion guided targeted biopsyMagnetic resonance imaging - ultrasound fusion targeted biopsy outperforms standard approaches in detecting prostate cancer: A meta-analysisProstate cancer detection after a negative prostate biopsy: lessons learnt in the Cleveland Clinic experience.Risk-based prostate cancer screening.Optimising repeat prostate biopsy decisions and procedures.Prostate saturation biopsy following a first negative biopsy: state of the art.Optimization of prostate biopsy: review of technique and complications.Random biopsy: when, how many and where to take the cores?Biopsy sampling and histopathological markers for diagnosis of prostate cancer.Transperineal biopsy prostate cancer detection in first biopsy and repeat biopsy after negative transrectal ultrasound-guided biopsy: the Victorian Transperineal Biopsy Collaboration experience.The impact of African American race on prostate cancer detection on repeat prostate biopsy in a veteran population.Predicting prostate cancer at rebiopsies in patients with high-grade prostatic intraepithelial neoplasia: a study on 546 patients.Characteristics and clinical significance of prostate cancers missed by initial transrectal 12-core biopsy.A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.Fluctuation in prostate cancer gene 3 (PCA3) score in men undergoing first or repeat prostate biopsies.Human kallikrein-2 gene and protein expression predicts prostate cancer at repeat biopsy.How many cores should be taken in a repeat biopsy on patients in whom atypical small acinar proliferation has been identified in an initial transrectal prostate biopsy?Discordance between location of positive cores in biopsy and location of positive surgical margin following radical prostatectomy.Prostate cancer detection on transrectal ultrasonography-guided random biopsy despite negative real-time magnetic resonance imaging/ultrasonography fusion-guided targeted biopsy: reasons for targeted biopsy failure.Biomechanical modeling constrained surface-based image registration for prostate MR guided TRUS biopsy.Transrectal real-time tissue elastography targeted biopsy coupled with peak strain index improves the detection of clinically important prostate cancer.Contemporary pathologic characteristics and oncologic outcomes of prostate cancers missed by 6- and 12-core biopsy and diagnosed with a 21-core biopsy protocol.Clinical value of ERG, TFF3, and SPINK1 for molecular subtyping of prostate cancer.Application of transrectal ultrasound-guided repeat needle biopsy in the diagnosis of prostate cancer in Chinese population: A retrospective study.Analysis of repeated 24-core saturation prostate biopsy: Inverse association between asymptomatic histological inflammation and prostate cancer detection.Risk of repeat biopsy and prostate cancer detection after an initial extended negative biopsy: longitudinal follow-up from a prospective trial.Is it possible to predict low-volume and insignificant prostate cancer by core needle biopsies?Experiences of Uncertainty in Men With an Elevated PSA.Sampling of the anterior apical region results in increased cancer detection and upgrading in transrectal repeat saturation biopsy of the prostate.Transrectal ultrasound-guided prostate biopsies vs. magnetic resonance imaging ultrasound fusion targeted biopsies: Who are the best candidates?Transrectal ultrasound-guided prostate rebiopsy: How many core sampling should be applied to which patient?Prostate cancer: A valuable tool for prediction of repeat biopsy pathology.Prostate needle biopsies: interobserver variation and clinical consequences of histopathological re-evaluation.Transperineal template-guided biopsy for diagnosis of prostate cancer in patients with at least two prior negative biopsies.
P2860
Q30988469-FEDAC4AB-A806-43DE-9049-32F7E0EE7991Q33592442-950A53B6-4A33-47A5-93EF-504028BCC951Q33679272-06492138-0EF2-4EBA-BABB-2786A7863903Q35112929-D89CA1C3-7B55-410E-9C68-43E820229698Q36049175-9CDF2678-5CD9-4DF0-B22F-FF7C8DC602F2Q36118034-A4735A61-EC89-4D76-9768-935956BF4B6BQ36249431-7BAC5EB3-239A-44EC-818B-E811617B477CQ37108415-E9F1E74F-CCA4-413B-9502-6D59D484DB88Q37892629-47261B5B-73FA-4CC8-A8EC-A8385B4C6E2DQ37963657-E632D5DE-E651-4F2F-AB0A-07BD37E6A7C9Q37970859-5B8A3D4E-9001-47D1-A5E9-86EAE164B15CQ38027698-ACE1A14F-AA9F-465E-BAB3-908848EDA2C0Q38203986-4873EFD3-CCBA-4D39-93F2-31B37DEB2E76Q38218443-BEDD7B5F-1185-4A8B-8229-F1944B0C1C8BQ38256309-51F87341-820E-4B66-A80E-B0B8A9AD3D1DQ38430080-D3705573-5748-4955-A3BE-8947F7979B51Q38825859-C7D5AD53-87CD-43B2-A63D-71605E4140A4Q39972916-23D41110-7875-40A9-A8B0-7D49F15DF4D4Q39999906-923AE81D-9B18-46D9-9C3A-0A9563DC106AQ39999913-0B5580C9-C3DE-4A7F-AF7D-60EAE51E1F6FQ40167317-FE064FC4-6DD1-41E2-B9CA-3FE8A97D0813Q40226279-BABFFF01-2AC9-4A46-9470-2EF86425ECBCQ40243058-75023D69-8822-4A22-A5A1-4AC93BC28B63Q40400000-006265F5-5EAD-41FD-9765-9256E1750166Q40524688-568BABB5-A6BA-4295-84D0-5651AA13C54CQ40934950-728A6283-DDE8-42A2-B2F9-9A9CC3B30D87Q40977484-5CF9CF71-1A49-4A11-9E26-7155926C3822Q41901097-C2D8C10B-4378-43AC-A399-6425B89FA19AQ42173139-973D4FE0-1D23-4F27-9123-D777B6ABFBFDQ42363869-592CE8F2-DAE3-4066-BDDE-6501FCE3A6ADQ42413527-AB68AD1B-4DAD-419B-82E6-4B501811AB13Q43431647-80113CCF-3385-4C0B-8688-661B3F206907Q45972358-B803D017-41BC-4E11-959F-C01AA91CE686Q47104037-722AFCB8-C044-48E9-BEA8-649A04CFA985Q47734142-7D4D5870-6952-45E5-B907-8DD32364CE22Q48518147-3CBFADDD-C984-4083-BD00-A9F73CF2B95CQ49441750-10F28753-883E-41AD-B4C7-AC5A2BDCAD6AQ49540099-FFA37B40-0EDD-4587-BD36-4B2C9D947DD3Q51578950-0AE62D90-3FB5-4386-B6BF-D6F3814474F2Q53094471-BA1223FB-1170-4DD3-A992-FA2A8F3D490A
P2860
Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Prostate cancer detection rate ...... ended 21-sample needle biopsy.
@en
Prostate cancer detection rate ...... ended 21-sample needle biopsy.
@nl
type
label
Prostate cancer detection rate ...... ended 21-sample needle biopsy.
@en
Prostate cancer detection rate ...... ended 21-sample needle biopsy.
@nl
prefLabel
Prostate cancer detection rate ...... ended 21-sample needle biopsy.
@en
Prostate cancer detection rate ...... ended 21-sample needle biopsy.
@nl
P2093
P1433
P1476
Prostate cancer detection rate ...... ended 21-sample needle biopsy.
@en
P2093
Alexandre de la Taille
Andras Hoznek
Claude Clément Abbou
Dimitri Vordos
Francis Vacherot
Grégoire Robert
Jean Jacques Patard
Jean-Louis Campos-Fernandes
Laurence Bastien
Laurent Salomon
P304
P356
10.1016/J.EURURO.2008.06.043
P407
P577
2008-06-23T00:00:00Z